<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04495218</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/52</org_study_id>
    <nct_id>NCT04495218</nct_id>
  </id_info>
  <brief_title>NGS Panel of Incomplete Forms of Ocular Albinism</brief_title>
  <acronym>DIA</acronym>
  <official_title>Implementation of a Next-generation Sequencing Analysis of a Panel of Genes Implicated in Incomplete Forms of Albinism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Implementation of a next-generation sequencing panel of genes to identify deleterious&#xD;
      variants in patients with incomplete forms of albinism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scientific context : Albinism is clinically characterised by cutaneous hypopigmentation and&#xD;
      ophthalmologic features. These features common to all forms of albinism are foveal&#xD;
      hypoplasia, misrouting of the optic nerves at the chiasm, retinal hypopigmentation,&#xD;
      translucent irides and nystagmus. The molecular genetic lab at Bordeaux University Hospital&#xD;
      is the national reference for the study of this disease. More than 1400 patients have been&#xD;
      analyzed with a strategy including next-generation sequencing of the 19 known genes of&#xD;
      albinism and array-CGH. Despite this thorough analysis, 25% of patients remain without&#xD;
      molecular diagnosis. Our experience tells us that these patients often show an incomplete&#xD;
      form of albinism with the presence of only few ophthalmologic signs. The molecular diagnosis&#xD;
      is very challenging as the phenotype often overlaps with other ophthalmologic disorders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2020</start_date>
  <completion_date type="Anticipated">May 23, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients for whom a molecular diagnosis is obtained based on the panel of targeted genes</measure>
    <time_frame>Enrollment</time_frame>
    <description>the prevalence of finding at least two pathogenic variants is 10%.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Albinism, Ocular</condition>
  <arm_group>
    <arm_group_label>Patient with a diagnosis of incomplete form of albinism</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Performed a 10 ml blood sample (2 unnamed samples of 5ml) in each of the 100 patients included.</description>
    <arm_group_label>Patient with a diagnosis of incomplete form of albinism</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a clinical diagnosis of incomplete form of albinism with presence of at least&#xD;
        2 signs of ocular albinism among which nystagmus, low vision, foveal hypoplasia, retinal&#xD;
        hypopigmentation, translucent irides, misrouting of the optic nerves at the chiasm and&#xD;
        having a specialized consultation in CHU de Bordeaux&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minor and adult patient.&#xD;
&#xD;
          -  Patient presenting a clinical diagnosis of incomplete form of albinism with presence&#xD;
             of at least 2 signs of ocular albinism among which nystagmus, low vision, foveal&#xD;
             hypoplasia, retinal hypopigmentation, translucent irides, misrouting of the optic&#xD;
             nerves at the chiasm.&#xD;
&#xD;
          -  Registered for the social security system.&#xD;
&#xD;
          -  Informed consent signed by patient or parent of a minor patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate in research protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eulalie LASSEAUX</last_name>
    <phone>0557820193</phone>
    <email>eulalie.lasseaux@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent MICHAUD</last_name>
    <phone>0557820353</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eulalie Lasseaux</last_name>
      <phone>0557820193</phone>
      <email>eulalie.lasseaux@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Vincent Michaud</last_name>
      <phone>0557820353</phone>
      <email>vincent.michaud@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Next generation sequencing</keyword>
  <keyword>Albinism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albinism</mesh_term>
    <mesh_term>Albinism, Ocular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

